P61.06 Participants With Family History of Cancer Have a Higher Participation Rate of Low-Dose Computed Tomography for Lung Cancer Screening

Abstract

Family history of cancer is an important risk factor for lung cancer. Studies have shown that it may also affect the willingness to lung cancer screening. To describe the low-dose computed tomography (LDCT) participation rate with a history of common cancers in a population-based screening program. The analysis was conducted in the context of the Cancer Screening Program in Urban China, which recruited 282,377 eligible participants aged 40-74 years from 8 cities in Henan province from 2013 to 2019. A total of 55,428 participants were evaluated to be high-risk for lung cancer by an established risk score system and were subsequently recommended for LDCT. In this study, we calculated the overall and group-specific participation rates by a family history of common cancers, as well as compared the differences in participation rates between different groups. Obtain odds ratios (ORs) and 95% CIs derived by multiple logistic regression model. Of 55,428 with high-risk for lung cancer, 22,260 subjects undertook LDCT (participation rate of 40.16%). We found that a family history of lung cancer, esophageal cancer, stomach cancer, liver cancer, and colorectal cancer were associated with increased participation in LDCT screening. The odds of participants with a family history of one cancer, two cancers, three cancers, and four or more cancers undertaking LDCT screening were 0.9-fold, 1.7-fold, 1.8-fold, and 2.5-fold higher than participants with no family history of cancer (OR: 1.88, 95% CI: 1.80-1.96; OR: 2.65, 95% CI: 2.51-2.79; OR: 2.83, 95% CI: 2.64-3.04; OR: 3.46, 95% CI: 3.15-3.79), respectively. Compared with those without a history of cancer, as the number of cancer family history increases, compliance gradually increases (P<0.001). There was room for improvement regarding lung cancer screening yield given the relatively low participation rate. Lung cancer screening in populations with a family history of cancer may be a choice.